This project explores high-risk CLL evolution, focusing on patients with TP53 mutations, unmutated IGHV, and complex karyotypes. After one year of venetoclax and obinutuzumab treatment, they will analyze early progression using single-cell RNA sequencing and whole-exome sequencing to track mutations. This aims to uncover tumor evolution and resistance mechanisms, providing insights into the long-term effects of fixed-duration therapies.
PRINCIPAL INVESTIGATOR
TRIO Research Center
University of Cologne
Robert-Koch-Straße 21
50931 Cologne
Department of Translational Genomics
University of Cologne
Weyertal 115b
50931 Cologne
German CLL Study Group
Department I of Internal Medicine
University Hospital of Cologne
Kerpener Straße 62
50937 Cologne
Project Interactions
-
A06
Understanding resistance towards BCL2-inhibition in CLL by exploring lytic and non-lytic mechanisms of programmed cell death
Dr. med. Lukas Frenzel -
B01
Dissecting the role of tyrosine kinases as key regulators and therapeutic targets in the microenvironment of chronic lymphocytic leukemia
Prof. Dr. med. Michael Hallek -
C05
Characterization of Richter-transformed lymphoma and genomic instability as a potential vulnerability in 17p-deleted lymphomas
Prof. Dr. med. Björn Chapuy, Prof. Dr. med. Barbara Eichhorst